Accelerator Mass Spectrometry-Enabled Studies: Current Status and Future Prospects

• Frey EF . The earliest medical texts. Clio. Med. 20(1–4), 79–90 (1985).
   PubMedGoogle Scholar
• Elmore D , PhillipsFM. Accelerator mass spectrometry for measurement of long-lived radioisotopes. Science236(4801), 543–550 (1987).
   PubMed Web of Science ®Google Scholar
• Turteltaub KW , FeltonJS, GledhillBLet al. Accelerator mass spectrometry in biomedical dosimetry. relationship between low-level exposure and covalent binding of heterocyclic amine carcinogens to DNA. Proc. Natl Acad. Sci. USA87(14), 5288–5292 (1990).
   PubMed Web of Science ®Google Scholar
• Gilman SD , GeeSJ, HammockBDet al. Analytical performance of accelerator mass spectrometry and liquid scintillation counting for detection of 14C-labeled atrazine metabolites in human urine. Anal. Chem. 70(16), 3463–3469 (1998).
   PubMed Web of Science ®Google Scholar
• Garner RC , BarkerJ, FlavellCet al. A validation study comparing accelerator MS and liquid scintillation counting for analysis of 14C-labelled drugs in plasma, urine and faecal extracts. J. Pharm. Biomed. Anal. 24(2), 197–209 (2000).
   PubMed Web of Science ®Google Scholar
• Brown P , GarnerC, GlassR, RidgwayC, HartA. Comparison of accelerator mass spectrometry with gas chromatography for the determination of pesticide residues in individual items in the diets of wild birds and mammals. J. Agric. Food Chem. 52(12), 3693–3701 (2004).
   PubMed Web of Science ®Google Scholar
• Liberman RG , TannenbaumSR, HugheyBJet al. An interface for direct analysis of 14C in nonvolatile samples by accelerator mass spectrometry. Anal. Chem. 76(2), 328–334 (2004).
   PubMed Web of Science ®Google Scholar
• Flarakos J , LibermanRG, TannenbaumSR, SkipperPL. Integration of continuous-flow accelerator mass spectrometry with chromatography and mass-selective detection. Anal. Chem. 80(13), 5079–5085 (2008).
   PubMed Web of Science ®Google Scholar
• Mcintyre CP , SylvaSP, RobertsML. Gas chromatograph–combustion system for (14)C-accelerator mass spectrometry. Anal. Chem. 81(15), 6 (2009).
   Web of Science ®Google Scholar
• Zoppi U , CryeJ, SongQ, ArjomandA. Performance evaluation of the new AMS system at Accium BioSciences. Radiocarbon49(1), 10 (2007).
   Web of Science ®Google Scholar
• Young GC , CorlessS, FelgateCC, ColthupPV. Comparison of a 250 KV single-stage accelerator mass spectrometer with a 5 MV tandem accelerator mass spectrometer – fitness for purpose in bioanalysis. Rapid Commun. Mass Spectrom. 22(24), 4035–4042 (2008).
   PubMed Web of Science ®Google Scholar
• Salehpour M , PossnertG, BryhniH. Subattomole sensitivity in biological accelerator mass spectrometry. Anal. Chem. 80(10), 3515–3521 (2008).
   PubMed Web of Science ®Google Scholar
• Salehpour M , PossnertG, BryhniH, Palminger-HallenI, StahleL. Biological accelerator mass spectrometry at Uppsala University. Appl. Radiat. Isot. 67(3), 495–499 (2009).
   PubMed Web of Science ®Google Scholar
• Salehpour M , ForsgardN, PossnertG. Femtomolar measurements using accelerator mass spectrometry. Rapid Commun. Mass Spectrom. 23(5), 557–563 (2009).
   PubMed Web of Science ®Google Scholar
• Vogel JS , TurteltaubKW, FinkelR, NelsonDE. Accelerator mass spectrometry. Anal. Chem. 67(11), 353A–359A (1995).
   PubMed Web of Science ®Google Scholar
• Brown K , DingleyKH, TurteltaubKW. Accelerator mass spectrometry for biomedical research. Methods Enzymol. 402, 423–443 (2005).
   PubMed Web of Science ®Google Scholar
• Hellborg R , SkogG. Accelerator mass spectrometry. Mass Spectrom. Rev. 27(5), 398–427 (2008).
   PubMedGoogle Scholar
• Vogel JS . Rapid production of graphite without contamination for biomedical AMS. Radiocarbon34, 344–350 (1992).
   Web of Science ®Google Scholar
• Ognibene TJ , BenchG, VogelJS, PeasleeGF, MurovS. A high-throughput method for the conversion of CO2 obtained from biochemical samples to graphite in septa-sealed vials for quantification of 14C via accelerator mass spectrometry. Anal. Chem. 75(9), 2192–2196 (2003).
   PubMed Web of Science ®Google Scholar
• Kim SH , KellyPB, CliffordAJ. Biological/biomedical accelerator mass spectrometry targets. 2. Physical, morphological, and structural characteristics. Anal. Chem. 80(20), 7661–7669 (2008).
   PubMed Web of Science ®Google Scholar
• Kim SH , KellyPB, CliffordAJ. Biological/biomedical accelerator mass spectrometry targets. 1. Optimizing the CO2 reduction step using zinc dust. Anal. Chem. 80(20), 7651–7660 (2008).
   PubMed Web of Science ®Google Scholar
• Kim SH , KellyPB, CliffordAJ. Accelerator mass spectrometry targets of submilligram carbonaceous samples using the high-throughput Zn reduction method. Anal. Chem. 81(14), 5949–5954 (2009).
   PubMed Web of Science ®Google Scholar
• Salehpour M , ForsgardN, PossnertG. Accelerator mass spectrometry of small biological samples. Rapid Commun. Mass Spectrom. 22(23), 3928–3934 (2008).
   PubMed Web of Science ®Google Scholar
• Buchholz BA , DuekerSR, LinY, CliffordAJ, VogelJ. Methods and applications of HPLC-AMS. Nucl. Instrum. Methods Phys. Res. B (192), 5 (2000).
   Google Scholar
• Lappin G , SimpsonM, ShishikuraY, GarnerC. High-performance liquid chromatography accelerator mass spectrometry. Correcting for losses during analysis by internal standardization. Anal. Biochem. 378(1), 93–95 (2008).
   PubMed Web of Science ®Google Scholar
• Dingley KH , UbickEA, VogelJS, HaackKW. DNA isolation and sample preparation for quantification of adduct levels by accelerator mass spectrometry. Methods Mol. Biol. 291, 21–27 (2005).
   PubMedGoogle Scholar
• Vogel JS , LoveAH. Quantitating isotopic molecular labels with accelerator mass spectrometry. Methods Enzymol. 402, 402–422 (2005).
   PubMed Web of Science ®Google Scholar
• Shan G , HuangW, GeeSJ, BuchholzBA, VogelJS, HammockBD. Isotope-labeled immunoassays without radiation waste. Proc. Natl Acad. Sci. USA97(6), 2445–2449 (2000).
   PubMed Web of Science ®Google Scholar
• Hah SS , MundtJM, KimHM, SumbadRA, TurteltaubKW, HendersonPT. Measurement of 7,8-dihydro-8-oxo-2´-deoxyguanosine metabolism in MCF-7 cells at low concentrations using accelerator mass spectrometry. Proc. Natl Acad. Sci. USA104(27), 11203–11208 (2007).
   PubMed Web of Science ®Google Scholar
• Stites TE , BaileyLB, ScottKC, TothJP, FisherWP, GregoryJF3rd. Kinetic modeling of folate metabolism through use of chronic administration of deuterium-labeled folic acid in men. Am. J. Clin. Nutr. 65(1), 53–60 (1997).
   PubMed Web of Science ®Google Scholar
• Stenstrom K , Leide-SvegbornS, ErlandssonBet al. Application of accelerator mass spectrometry (AMS) for high-sensitivity measurements of 14CO2 in long-term studies of fat metabolism. Appl. Radiat. Isot. 47(4), 417–422 (1996).
   PubMed Web of Science ®Google Scholar
• Clifford AJ , ArjomandA, DuekerSR, SchneiderPD, BuchholzBA, VogelJS. The dynamics of folic acid metabolism in an adult given a small tracer dose of 14C-folic acid. Adv. Exp. Med. Biol. 445, 239–251 (1998).
   PubMed Web of Science ®Google Scholar
• Buchholz BA , ArjomandA, DuekerSR, SchneiderPD, CliffordAJ, VogelJS. Intrinsic erythrocyte labeling and attomole pharmacokinetic tracing of 14C-labeled folic acid with accelerator mass spectrometry. Anal. Biochem. 269(2), 348–352 (1999).
   PubMed Web of Science ®Google Scholar
• Lin Y , DuekerSR, FollettJRet al. Quantitation of in vivo human folate metabolism. Am. J. Clin. Nutr. 80(3), 680–691 (2004).
   PubMed Web of Science ®Google Scholar
• Dueker SR , LinY, BuchholzBAet al. Long-term kinetic study of β-carotene, using accelerator mass spectrometry in an adult volunteer. J. Lipid Res. 41(11), 1790–1800 (2000).
   PubMed Web of Science ®Google Scholar
• Hickenbottom SJ , LemkeSL, DuekerSRet al. Dual isotope test for assessing β-carotene cleavage to vitamin A in humans. Eur. J. Nutr. 41(4), 141–147 (2002).
   PubMed Web of Science ®Google Scholar
• Lemke SL , DuekerSR, FollettJRet al. Absorption and retinol equivalence of β-carotene in humans is influenced by dietary vitamin A intake. J. Lipid Res. 44(8), 1591–1600 (2003).
   PubMed Web of Science ®Google Scholar
• Ho CC , DE Moura FF, Kim SH, Clifford AJ. Excentral cleavage of β-carotene in vivo in a healthy man. Am. J. Clin. Nutr. 85(3), 770–777 (2007).
   PubMed Web of Science ®Google Scholar
• Ho CC , De Moura FF, Kim SH, Burri BJ, Clifford AJ. A minute dose of 14C–β-carotene is absorbed and converted to retinoids in humans. J. Nutr. 139(8), 1480–1486 (2009).
   PubMed Web of Science ®Google Scholar
• De Moura FF , HoCC, GetachewG, HickenbottomS, CliffordAJ. Kinetics of 14C distribution after tracer dose of 14C-lutein in an adult woman. Lipids40(10), 1069–1073 (2005).
   PubMed Web of Science ®Google Scholar
• Carkeet C , DuekerSR, LangoJet al. Human vitamin B12 absorption measurement by accelerator mass spectrometry using specifically labeled (14)C-cobalamin. Proc. Natl Acad. Sci. USA103(15), 5694–5699 (2006).
   PubMed Web of Science ®Google Scholar
• Clifford AJ , De Moura FF, Ho CCet al. A feasibility study quantifying in vivo human α-tocopherol metabolism. Am. J. Clin. Nutr. 84(6), 1430–1441 (2006).
   PubMed Web of Science ®Google Scholar
• Garner RC , LightfootTJ, CupidBCet al. Comparative biotransformation studies of MeIQx and PhIP in animal models and humans. Cancer Lett. 143(2), 161–165 (1999).
   PubMed Web of Science ®Google Scholar
• Dingley KH , CurtisKD, NowellS, FeltonJS, LangNP, TurteltaubKW. DNA and protein adduct formation in the colon and blood of humans after exposure to a dietary-relevant dose of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. Cancer Epidemiol. Biomarkers Prev. 8(6), 507–512 (1999).
   PubMed Web of Science ®Google Scholar
• Turteltaub KW , DingleyKH, CurtisKDet al. Macromolecular adduct formation and metabolism of heterocyclic amines in humans and rodents at low doses. Cancer Lett. 143(2), 149–155 (1999).
   PubMed Web of Science ®Google Scholar
• Malfatti MA , DingleyKH, Nowell-KadlubarSet al. The urinary metabolite profile of the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine is predictive of colon DNA adducts after a low-dose exposure in humans. Cancer Res. 66(21), 10541–10547 (2006).
   PubMed Web of Science ®Google Scholar
• Cupid BC , LightfootTJ, RussellDet al. The formation of AFB(1)-macromolecular adducts in rats and humans at dietary levels of exposure. Food Chem. Toxicol. 42(4), 559–569 (2004).
   PubMed Web of Science ®Google Scholar
• Mauthe RJ , DingleyKH, LevesonSHet al. Comparison of DNA-adduct and tissue-available dose levels of MeIQx in human and rodent colon following administration of a very low dose. Int. J. Cancer80(4), 539–545 (1999).
   PubMed Web of Science ®Google Scholar
• Dingley KH , FreemanSP, NelsonDO, GarnerRC, TurteltaubKW. Covalent binding of 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline to albumin and hemoglobin at environmentally relevant doses. Comparison of human subjects and F344 rats. Drug Metab. Dispos. 26(8), 825–828 (1998).
   PubMed Web of Science ®Google Scholar
• Turteltaub KW , MautheRJ, DingleyKHet al. MeIQx-DNA adduct formation in rodent and human tissues at low doses. Mutat. Res. 376(1–2), 243–252 (1997).
   PubMed Web of Science ®Google Scholar
• Mauthe RJ , SnyderwineEG, GhoshalA, FreemanSP, TurteltaubKW. Distribution and metabolism of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PHiP) in female rats and their pups at dietary doses. Carcinogenesis19(5), 919–924 (1998).
   PubMed Web of Science ®Google Scholar
• Cheng Y , LiHL, WangHFet al. Inhibition of nicotine-DNA adduct formation in mice by six dietary constituents. Food Chem. Toxicol. 41(7), 1045–1050 (2003).
   PubMed Web of Science ®Google Scholar
• Li H , ChengY, WangHet al. Inhibition of nitrobenzene-induced DNA and hemoglobin adductions by dietary constituents. Appl. Radiat. Isot. 58(3), 291–298 (2003).
   PubMed Web of Science ®Google Scholar
• Rickert DE , DingleyK, UbickE, DixKJ, MolinaL. Determination of the tissue distribution and excretion by accelerator mass spectrometry of the nonadecapeptide 14C-Moli1901 in beagle dogs after intratracheal instillation. Chem. Biol. Interact. 155(1–2), 55–61 (2005).
   PubMed Web of Science ®Google Scholar
• DeGregorio MW , DingleyKH, WurzGT, UbickE, TurteltaubKW. Accelerator mass spectrometry allows for cellular quantification of doxorubicin at femtomolar concentrations. Cancer Chemother. Pharmacol. 57(3), 335–342 (2006).
   PubMed Web of Science ®Google Scholar
• Leide-Svegborn S , StenstromK, OlofssonMet al. Biokinetics and radiation doses for carbon-14 urea in adults and children undergoing the Helicobacter pylori breath test. Eur. J. Nucl. Med. 26(6), 573–580 (1999).
   PubMedGoogle Scholar
• Gunnarsson M , Leide-SvegbornS, StenstromKet al. No radiation protection reasons for restrictions on 14C urea breath tests in children. Br. J. Radiol. 75(900), 982–986 (2002).
   PubMed Web of Science ®Google Scholar
• Combes RD , BerridgeT, ConnellyJet al. Early microdose drug studies in human volunteers can minimise animal testing. Proceedings of a workshop organised by volunteers in research and testing. Eur. J. Pharm. Sci. 19(1), 1–11 (2003).
   PubMed Web of Science ®Google Scholar
• Lappin G , GarnerRC. Big physics, small doses. The use of AMS and PET in human microdosing of development drugs. Nat. Rev. Drug Discov. 2(3), 233–240 (2003).
   PubMed Web of Science ®Google Scholar
• Buchan P . Smarter candidate selection – utilizing microdosing in exploratory clinical studies. Ernst Schering Res. Found Workshop59, 7–27 (2007).
   PubMedGoogle Scholar
• Butz RF , MorelliG. Innovative strategies for early clinical R&D. IDrugs11(1), 36–41 (2008).
   PubMedGoogle Scholar
• Carpenter AP , PontecorvoMJ, HeftiFF, SkovronskyDM. The use of the exploratory IND in the evaluation and development of 18F-PET radiopharmaceuticals for amyloid imaging in the brain. A review of one company’s experience. Q. J. Nucl. Med. Mol. Imaging53(4), 387–393 (2009).
   PubMed Web of Science ®Google Scholar
• Jacobson-Kram D , MillsG. Leveraging exploratory investigational new drug studies to accelerate drug development. Clin. Cancer Res. 14(12), 3670–3674 (2008).
   PubMed Web of Science ®Google Scholar
• Kummar S , RubinsteinL, KindersRet al. Phase 0 clinical trials. Conceptions and misconceptions. Cancer J. 14(3), 133–137 (2008).
   PubMed Web of Science ®Google Scholar
• Sarapa N . Exploratory IND. A new regulatory strategy for early clinical drug development in the United States. Ernst Schering Res. Found. Workshop (59), 151–163 (2007).
   PubMedGoogle Scholar
• Balani SK , NagarajaNV, QianMGet al. Evaluation of microdosing to assess pharmacokinetic linearity in rats using liquid chromatography–tandem mass spectrometry. Drug Metab. Dispos. 34(3), 384–388 (2006).
   PubMed Web of Science ®Google Scholar
• Bauer M , LangerO, Dal-BiancoPet al. A positron emission tomography microdosing study with a potential antiamyloid drug in healthy volunteers and patients with Alzheimer’s disease. Clin. Pharmacol. Ther. 80(3), 216–227 (2006).
   PubMed Web of Science ®Google Scholar
• Bauer M , WagnerCC, LangerO. Microdosing studies in humans. The role of positron emission tomography. Drugs RD9(2), 73–81 (2008).
   PubMed Web of Science ®Google Scholar
• Sandhu P , VogelJS, RoseMJet al. Evaluation of microdosing strategies for studies in preclinical drug development. Demonstration of linear pharmacokinetics in dogs of a nucleoside analog over a 50-fold dose range. Drug Metab. Dispos. 32(11), 1254–1259 (2004).
   PubMed Web of Science ®Google Scholar
• Lappin G , KuhnzW, JochemsenRet al. Use of microdosing to predict pharmacokinetics at the therapeutic dose. Experience with 5 drugs. Clin. Pharmacol. Ther. 80(3), 203–215 (2006).
   PubMed Web of Science ®Google Scholar
• Vuong L , RuckleJL, BloodABet al. Use of accelerator mass spectrometry to measure the pharmacokinetics and peripheral blood mononuclear cell concentrations of zidovudine. J Pharm Sci97(7), 2833–2843 (2008).
   PubMed Web of Science ®Google Scholar
• Garner C . New paradigm of early clinical research – EUMAPP. Parliament Magazine238, 1 (2007).
   Google Scholar
• Zhou XJ , GarnerRC, NicholsonS, KisslingCJ, MayersD. Microdose pharmacokinetics of IDX899 and IDX989, candidate HIV-1 non-nucleoside reverse transcriptase inhibitors, following oral and intravenous administration in healthy male subjects. J. Clin. Pharmacol. (2009).
   Google Scholar
• Young G , EllisW, AyrtonJ, HusseyE, AdamkiewiczB. Accelerator mass spectrometry (AMS). Recent experience of its use in a clinical study and the potential future of the technique. Xenobiotica31(8–9), 619–632 (2001).
   PubMed Web of Science ®Google Scholar
• Garner RC , GarnerJV, GregoryS, WhattamM, CalamA, LeongD. Comparison of the absorption of micronized (Daflon 500 mg) and nonmicronized 14C-diosmin tablets after oral administration to healthy volunteers by accelerator mass spectrometry and liquid scintillation counting. J. Pharm. Sci. 91(1), 32–40 (2002).
   PubMed Web of Science ®Google Scholar
• Boddy AV , SluddenJ, GriffinMJet al. Pharmacokinetic investigation of imatinib using accelerator mass spectrometry in patients with chronic myeloid leukemia. Clin. Cancer Res. 13(14), 4164–4169 (2007).
   PubMed Web of Science ®Google Scholar
• Garner RC , GorisI, LaenenAAet al. Evaluation of accelerator mass spectrometry in a human mass balance and pharmacokinetic study-experience with 14C-labeled (r)-6-[amino(4- chlorophenyl)(1-methyl-1h-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1- methyl-2(1h)-quinolinone (r115777), a farnesyl transferase inhibitor. Drug Metab. Dispos. 30(7), 823–830 (2002).
   PubMed Web of Science ®Google Scholar
• Sarapa N , HsyuPH, LappinG, GarnerRC. The application of accelerator mass spectrometry to absolute bioavailability studies in humans. Simultaneous administration of an intravenous microdose of 14C-nelfinavir mesylate solution and oral nelfinavir to healthy volunteers. J. Clin. Pharmacol. 45(10), 1198–1205 (2005).
   PubMed Web of Science ®Google Scholar
• Miyaji Y , IshizukaT, KawaiKet al. Use of an intravenous microdose of 14C-labeled drug and accelerator mass spectrometry to measure absolute oral bioavailability in dogs; cross-comparison of assay methods by accelerator mass spectrometry and liquid chromatography-tandem mass spectrometry. Drug Metab. Pharmacokinet. 24(2), 130–138 (2009).
   PubMed Web of Science ®Google Scholar
• Klem B , LappinG, NicholsonSet al. Determination of the bioavailability of [14C]-hexaminolevulinate using accelerator mass spectrometry after intravesical administration to human volunteers. J. Clin. Pharmacol. 46(4), 456–460 (2006).
   PubMed Web of Science ®Google Scholar
• Beumer JH , GarnerRC, CohenMBet al. Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry. Invest. New Drugs25(4), 327–334 (2007).
   PubMed Web of Science ®Google Scholar
• Prakash C , ShafferCL, TremaineLMet al. Application of liquid chromatography–accelerator mass spectrometry (LC–AMS) to evaluate the metabolic profiles of a drug candidate in human urine and plasma. Drug Metab. Lett. 1(3), 226–231 (2007).
   PubMedGoogle Scholar
• Lappin G , GarnerRC, MeyersT, PowellJ, VarleyP. Novel use of accelerator mass spectrometry for the quantification of low levels of systemic therapeutic recombinant protein. J. Pharm. Biomed. Anal. 41(4), 1299–1302 (2006).
   PubMed Web of Science ®Google Scholar
• Nakamura T . [Applications of low-abundance-radioisotope measurements with accelerator mass spectrometry to the biomedical sciences]. Tanpakushitsu Kakusan Koso39(11), 2011–2020 (1994).
   PubMedGoogle Scholar
• Kaye B , GarnerRC, MautheRJ, FreemanSP, TurteltaubKW. A preliminary evaluation of accelerator mass spectrometry in the biomedical field. J. Pharm. Biomed. Anal. 16(3), 541–543 (1997).
   PubMed Web of Science ®Google Scholar
• Barker J , GarnerRC. Biomedical applications of accelerator mass spectrometry-isotope measurements at the level of the atom. Rapid Commun. Mass Spectrom. 13(4), 285–293 (1999).
   PubMed Web of Science ®Google Scholar
• Garner RC . Accelerator mass spectrometry in pharmaceutical research and development – a new ultrasensitive analytical method for isotope measurement. Curr. Drug Metab. 1(2), 205–213 (2000).
   PubMed Web of Science ®Google Scholar
• Turteltaub KW , VogelJS. Bioanalytical applications of accelerator mass spectrometry for pharmaceutical research. Curr. Pharm. Des. 6(10), 991–1007 (2000).
   PubMed Web of Science ®Google Scholar
• Papac DI , ShahrokhZ. Mass spectrometry innovations in drug discovery and development. Pharm Res18(2), 131–145 (2001).
   PubMed Web of Science ®Google Scholar
• Lappin G , GarnerRC. Current perspectives of 14C-isotope measurement in biomedical accelerator mass spectrometry. Anal. Bioanal. Chem. 378(2), 356–364 (2004).
   PubMed Web of Science ®Google Scholar
• White IN , BrownK. Techniques. The application of accelerator mass spectrometry to pharmacology and toxicology. Trends Pharmacol. Sci. 25(8), 442–447 (2004).
   PubMed Web of Science ®Google Scholar
• Lappin G , GarnerRC. The use of accelerator mass spectrometry to obtain early human ADME/PK data. Expert Opin. Drug Metab. Toxicol. 1(1), 23–31 (2005).
   PubMedGoogle Scholar
• Palmblad M , BuchholzBA, HillegondsDJ, VogelJS. Neuroscience and accelerator mass spectrometry. J. Mass Spectrom. 40(2), 154–159 (2005).
   PubMed Web of Science ®Google Scholar
• Vogel JS . Accelerator mass spectrometry for quantitative in vivo tracing. Biotechniques (Suppl.) 25–29 (2005).
   Google Scholar
• Brown K , TompkinsEM, WhiteIN. Applications of accelerator mass spectrometry for pharmacological and toxicological research. Mass Spectrom. Rev. 25(1), 127–145 (2006).
   PubMed Web of Science ®Google Scholar
• Lappin G , StevensL. Biomedical accelerator mass spectrometry. Recent applications in metabolism and pharmacokinetics. Expert Opin. Drug Metab. Toxicol. 4(8), 1021–1033 (2008).
   PubMed Web of Science ®Google Scholar
• Larsson M . Editorial. Accelerator mass spectrometry. Mass Spectrom. Rev. 27(5), 397 (2008).
   PubMedGoogle Scholar
• Hah SS . Recent advances in biomedical applications of accelerator mass spectrometry. J. Biomed. Sci. 16, 54 (2009).
   PubMed Web of Science ®Google Scholar
• Gunnarsson M , StenstromK, Leide-SvegbornSet al. Biokinetics and radiation dosimetry for patients undergoing a glycerol tri[1–14C]oleate fat malabsorption breath test. Appl. Radiat. Isot. 58(4), 517–526 (2003).
   PubMed Web of Science ®Google Scholar
• Gunnarsson M , Leide-SvegbornS, StenstromKet al. Long-term biokinetics and radiation exposure of patients undergoing 14C-glycocholic acid and 14C-xylose breath tests. Cancer Biother. Radiopharm. 22(6), 762–771 (2007).
   PubMed Web of Science ®Google Scholar
• Shapiro SD , EndicottSK, ProvinceMA, PierceJA, CampbellEJ. Marked longevity of human lung parenchymal elastic fibers deduced from prevalence of D-aspartate and nuclear weapons-related radiocarbon. J. Clin. Invest. 87(5), 1828–1834 (1991).
   PubMed Web of Science ®Google Scholar
• Bergmann O , BhardwajRD, BernardSet al. Evidence for cardiomyocyte renewal in humans. Science324(5923), 98–102 (2009).
   PubMed Web of Science ®Google Scholar
• Bhardwaj RD , CurtisMA, SpaldingKLet al. Neocortical neurogenesis in humans is restricted to development. Proc. Natl Acad. Sci. USA103(33), 12564–12568 (2006).
   PubMed Web of Science ®Google Scholar
• Spalding KL , ArnerE, WestermarkPOet al. Dynamics of fat cell turnover in humans. Nature453(7196), 783–787 (2008).
   PubMed Web of Science ®Google Scholar
• Spalding KL , BuchholzBA, BergmanLE, DruidH, FrisenJ. Forensics. Age written in teeth by nuclear tests. Nature437(7057), 333–334 (2005).
   PubMed Web of Science ®Google Scholar
• Record RD , HillegondsD, SimmonsCet al. In vivo degradation of 14C-labeled small intestinal submucosa (sis) when used for urinary bladder repair. Biomaterials22(19), 2653–2659 (2001).
   PubMed Web of Science ®Google Scholar
• Gilbert TW , Stewart-AkersAM, BadylakSF. A quantitative method for evaluating the degradation of biologic scaffold materials. Biomaterials28(2), 147–150 (2007).
   PubMed Web of Science ®Google Scholar
• Li Y , ShawgoRS, TylerBet al. In vivo release from a drug delivery MEMS device. J. Control Release100(2), 211–219 (2004).
   PubMed Web of Science ®Google Scholar
• Buchholz BA , FreemanS, HaackK, VogelJ. Tips and traps in the 14C Bio-AMS preparation laboratory. Nucl. Instrum. Methods Phys. Res. B172, 5 (2000).
   Web of Science ®Google Scholar
• Hah SS . Determination of protein-ligand interactions using accelerator mass spectrometry. Modified crosslinking assay. Anal. Sci. 25(5), 731–733 (2009).
   PubMed Web of Science ®Google Scholar
• Minamimoto R , HamabeY, MiyaokaTet al. Accelerator mass spectrometry analysis of background 14C-concentrations in human blood. Aiming at reference data for further microdosing studies. Ann. Nucl. Med. 22(10), 883–889 (2008).
   PubMed Web of Science ®Google Scholar
• Nelson DE . A new method for carbon isotopic analysis of protein. Science251(4993), 552–554 (1991).
   PubMed Web of Science ®Google Scholar
• Palmblad M , BenchG, VogelJS. Mass by energy loss quantitation as a practical submicrogram balance. Anal. Chem. 77(3), 952–953 (2005).
   PubMed Web of Science ®Google Scholar
• Palmblad M , VogelJS. Quantitation of binding, recovery and desalting efficiency of peptides and proteins in solid phase extraction micropipette tips. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 814(2), 309–313 (2005).
   PubMed Web of Science ®Google Scholar
• Veltkamp AC . Radiochromatography in pharmaceutical and biomedical analysis. J. Chromatogr. 531, 101–129 (1990).
   PubMed Web of Science ®Google Scholar
• Bogen KT , KeatingGA, MeissnerS, VogelJS. Initial uptake kinetics in human skin exposed to dilute aqueous trichloroethylene in vitro. J. Expo. Anal. Environ. Epidemiol. 8(2), 253–271 (1998).
   PubMedGoogle Scholar
• Turteltaub KW , VogelJS, FrantzCE, ShenN. Fate and distribution of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine mice at a human dietary equivalent dose. Cancer Res. 52(17), 4682–4687 (1992).
   PubMed Web of Science ®Google Scholar
• Frantz CE , BangerterC, FultzE, MayerKM, VogelJS, TurteltaubKW. Dose-response studies of MeIQx in rat liver and liver DNA at low doses. Carcinogenesis16(2), 367–373 (1995).
   PubMed Web of Science ®Google Scholar
• Turteltaub KW , VogelJS, FrantzC, FeltonJS, McmanusM. Assessment of the DNA adduction and pharmacokinetics of PHiP and MeIQx in rodents at doses approximating human exposure using the technique of accelerator mass spectrometry (AMS) and 32P-postlabeling. Princess Takamatsu Symp. 23, 93–102 (1995).
   PubMedGoogle Scholar
• Creek MR , ManiC, VogelJS, TurteltaubKW. Tissue distribution and macromolecular binding of extremely low doses of [14C]-benzene in B6C3F1 mice. Carcinogenesis18(12), 2421–2427 (1997).
   PubMed Web of Science ®Google Scholar
• Martin EA , CarthewP, WhiteINet al. Investigation of the formation and accumulation of liver DNA adducts in mice chronically exposed to tamoxifen. Carcinogenesis18(11), 2209–2215 (1997).
   PubMed Web of Science ®Google Scholar
• White IN , MartinEA, MautheRJ, VogelJS, TurteltaubKW, SmithLI. Comparisons of the binding of [14C]radiolabelled tamoxifen or toremifene to rat DNA using accelerator mass spectrometry. Chem. Biol. Interact. 106(2), 149–160 (1997).
   PubMed Web of Science ®Google Scholar
• Garner RC . The role of DNA adducts in chemical carcinogenesis. Mutat. Res. 402(1–2), 67–75 (1998).
   PubMed Web of Science ®Google Scholar
• Buchholz BA , FultzE, HaackKWet al. HPLC-accelerator MS measurement of atrazine metabolites in human urine after dermal exposure. Anal. Chem. 71(16), 3519–3525 (1999).
   PubMed Web of Science ®Google Scholar
• Kwok ES , BuchholzBA, VogelJS, TurteltaubKW, EastmondDA. Dose-dependent binding of ortho-phenylphenol to protein but not DNA in the urinary bladder of male F344 rats. Toxicol. Appl. Pharmacol. 159(1), 18–24 (1999).
   PubMed Web of Science ®Google Scholar
• Lang NP , NowellS, MalfattiMAet al. In vivo human metabolism of [2–14C]2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PHiP). Cancer Lett. 143(2), 135–138 (1999).
   PubMed Web of Science ®Google Scholar
• Mani C , FreemanS, NelsonDO, VogelJS, TurteltaubKW. Species and strain comparisons in the macromolecular binding of extremely low doses of [14C]benzene in rodents, using accelerator mass spectrometry. Toxicol. Appl. Pharmacol. 159(2), 83–90 (1999).
   PubMed Web of Science ®Google Scholar
• Goldman R , DayBW, CarverTA, MautheRJ, TurteltaubKW, ShieldsPG. Quantitation of benzo[a]pyrene-DNA adducts by postlabeling with 14C-acetic anhydride and accelerator mass spectrometry. Chem. Biol. Interact. 126(3), 171–183 (2000).
   PubMed Web of Science ®Google Scholar
• Boocock DJ , BrownK, GibbsAH, SanchezE, TurteltaubKW, WhiteIN. Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA. Carcinogenesis23(11), 1897–1901 (2002).
   PubMed Web of Science ®Google Scholar
• Vogel JS , KeatingGA2nd, BuchholzBA. Protein binding of isofluorophate in vivo after coexposure to multiple chemicals. Environ. Health Perspect. 110(Suppl. 6), 1031–1036 (2002).
   PubMed Web of Science ®Google Scholar
• Williams KE , CarverTA, MirandaJJet al. Attomole detection of in vivo protein targets of benzene in mice. Evidence for a highly reactive metabolite. Mol. Cell. Proteomics1(11), 885–895 (2002).
   PubMed Web of Science ®Google Scholar
• Li H , WangH, SunH, LiuY, LiuK, PengS. Binding of nitrobenzene to hepatic DNA and hemoglobin at low doses in mice. Toxicol. Lett. 139(1), 25–32 (2003).
   PubMed Web of Science ®Google Scholar
• Martin EA , BrownK, GaskellMet al. Tamoxifen DNA damage detected in human endometrium using accelerator mass spectrometry. Cancer Res. 63(23), 8461–8465 (2003).
   PubMed Web of Science ®Google Scholar
• Turteltaub KW , ManiC. Benzene metabolism in rodents at doses relevant to human exposure from urban air. Res. Rep. Health Eff. Inst. (113), 1–26; discussion 27–35 (2003).
   PubMedGoogle Scholar
• Mally A , ZepnikH, WanekPet al. Ochratoxin A. Lack of formation of covalent DNA adducts. Chem. Res. Toxicol. 17(2), 234–242 (2004).
   PubMed Web of Science ®Google Scholar
• Du HF , XuLH, WangHFet al. Formation of MTBE-DNA adducts in mice measured with accelerator mass spectrometry. Environ. Toxicol. 20(4), 397–401 (2005).
   PubMed Web of Science ®Google Scholar
• Malfatti MA , UbickEA, FeltonJS. The impact of glucuronidation on the bioactivation and DNA adduction of the cooked-food carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in vivo. Carcinogenesis26(11), 2019–2028 (2005).
   PubMed Web of Science ®Google Scholar
• Mally A , DekantW. DNA adduct formation by ochratoxin a. Review of the available evidence. Food Addit. Contam. 22(Suppl. 1), 65–74 (2005).
   PubMedGoogle Scholar
• Hillier SM , MarquisJC, ZayasBet al. DNA adducts formed by a novel antitumor agent 11β-dichloro in vitro and in vivo. Mol. Cancer Ther. 5(4), 977–984 (2006).
   PubMedGoogle Scholar
• Skipper PL , TrudelLJ, KenslerTWet al. DNA adduct formation by 2,6-dimethyl-, 3,5-dimethyl-, and 3-ethylaniline in vivo in mice. Chem. Res. Toxicol. 19(8), 1086–1090 (2006).
   PubMed Web of Science ®Google Scholar
• Xie Q , SunH, LiuY, DingX, FuD, LiuK. Adduction of biomacromolecules with acrylamide (AA) in mice at environmental dose levels studied by accelerator mass spectrometry. Toxicol. Lett. 163(2), 101–108 (2006).
   PubMed Web of Science ®Google Scholar
• Brown K , TompkinsEM, BoocockDJet al. Tamoxifen forms DNA adducts in human colon after administration of a single [14C]-labeled therapeutic dose. Cancer Res. 67(14), 6995–7002 (2007).
   PubMed Web of Science ®Google Scholar
• Hah SS , SumbadRA, De Vere White RW, Turteltaub KW, Henderson PT. Characterization of oxaliplatin–DNA adduct formation in DNA and differentiation of cancer cell drug sensitivity at microdose concentrations. Chem. Res. Toxicol. 20(12), 1745–1751 (2007).
   PubMed Web of Science ®Google Scholar
• Watanabe K , LibermanRG, SkipperPL, TannenbaumSR, GuengerichFP. Analysis of DNA adducts formed in vivo in rats and mice from 1,2-dibromoethane, 1,2-dichloroethane, dibromomethane, and dichloromethane using HPLC/accelerator mass spectrometry and relevance to risk estimates. Chem. Res. Toxicol. 20(11), 1594–1600 (2007).
   PubMed Web of Science ®Google Scholar
• Yuan Y , WangHF, SunHFet al. Adduction of DNA with MTBE and TBA in mice studied by accelerator mass spectrometry. Environ. Toxicol. 22(6), 630–635 (2007).
   PubMed Web of Science ®Google Scholar
• Coldwell KE , CuttsSM, OgnibeneTJ, HendersonPT, PhillipsDR. Detection of adriamycin-DNA adducts by accelerator mass spectrometry at clinically relevant adriamycin concentrations. Nucleic Acids Res. 36(16), e100 (2008).
   PubMed Web of Science ®Google Scholar
• Knutson CG , SkipperPL, LibermanRG, TannenbaumSR, MarnettLJ. Monitoring in vivo metabolism and elimination of the endogenous DNA adduct, M1DG {3-(2-deoxy-β-D-erythro-pentofuranosyl)pyrimido[1,2-α]purin-10(3h)-one}, by accelerator mass spectrometry. Chem. Res. Toxicol. 21(6), 1290–1294 (2008).
   PubMed Web of Science ®Google Scholar
• Xie Q , LiuY, SunHet al. Inhibition of acrylamide toxicity in mice by three dietary constituents. J. Agric. Food Chem. 56(15), 6054–6060 (2008).
   PubMed Web of Science ®Google Scholar
• Marsden DA , JonesDJ, BrittonRGet al. Dose-response relationships for n7-(2-hydroxyethyl)guanine induced by low-dose [14C]ethylene oxide. Evidence for a novel mechanism of endogenous adduct formation. Cancer Res. 69(7), 3052–3059 (2009).
   PubMed Web of Science ®Google Scholar
• Eap CB , BuclinT, CucchiaGet al. Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity. Eur. J. Clin. Pharmacol. 60(4), 237–246 (2004).
   PubMed Web of Science ®Google Scholar
• Beumer JH , BeijnenJH, SchellensJH. Mass balance studies, with a focus on anticancer drugs. Clin. Pharmacokinet. 45(1), 33–58 (2006).
   PubMed Web of Science ®Google Scholar
• Lappin G , RowlandM, GarnerRC. The use of isotopes in the determination of absolute bioavailability of drugs in humans. Expert Opin. Drug Metab. Toxicol. 2(3), 419–427 (2006).
   PubMed Web of Science ®Google Scholar

Websites

• EMEA. Position Paper on Non-Clinical Safety Studies to Support Clinical Trials with a Single Microdose. June 2004 www.ema.europa.eu/pdfs/human/swp/259902en.pdf
   Google Scholar
• US FDA. Guidance for Industry, Investigators, and Reviewers – Exploratory IND Studies. January 2006 www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM078933.pdf
   Google Scholar
• US FDA. Guidance for Industry – Safety Testing of Drug Metabolites (2008) www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm079266.pdf
   Google Scholar